NIH-funded research R21 grant

Investigating a new bacterial pathway for sphingolipid production

Official title: Cryptic bacterial carrier proteins bridging fatty acid synthase

Funded at University of California, San Diego · NIH-11042269 · Data updated 2026-11-12

This study is exploring how certain bacteria, like E. coli and Staphylococcus aureus, make special fats called sphingolipids that we thought only come from our bodies, which could help us find new ways to fight infections.

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionUniversity of California, San Diego
NIH-funded
Lab location1 site (La Jolla, United States)
Project startMarch 1, 2024
Project endJanuary 31, 2026
Funding year2025
Award (this year)$171,565
NIH project number5R21AI180648-02
Project IDNIH-11042269 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals with infections caused by pathogenic bacteria such as E. coli or Staphylococcus aureus.

Less likely to help

Patients with infections caused by non-pathogenic bacteria or those not responsive to antibiotic treatment may not benefit from this research.

What this research studies

This research focuses on a newly discovered bacterial pathway that produces sphingolipids, which were previously thought to be exclusively derived from host organisms. The team is studying a unique acyl carrier protein, AcpSP, found in various pathogenic bacteria, including E. coli and Staphylococcus aureus. By utilizing advanced chemical and structural biology techniques, the researchers aim to understand how AcpSP interacts with other enzymes involved in sphingolipid biosynthesis. This could reveal new insights into bacterial pathogenesis and potential targets for antibiotic development.

Why it matters

Potential benefit: If successful, this research could lead to the development of new antibiotics targeting bacterial sphingolipid biosynthesis, improving treatment options for infections.

How similar studies have gone: Other research has shown promise in targeting bacterial biosynthetic pathways for antibiotic development, suggesting a potential for success in this novel approach.

Where this research is happening

  • University of California, San Diego
    La Jolla, United States
    Active

Researchers

  • Principal investigator: Burkart, Michael D. — University of California, San Diego
  • Study coordinator: Burkart, Michael D.

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.